• InMed announced a non-binding letter of intent to acquire BayMedica Inc.
• The move is designed to grow InMed’s market presence and strengthen its operations
• The two companies have had a reciprocal research collaboration that dates back to November 2020
• InMed looks to capitalize on the growing cannabinoid industry that is projected to grow at a CAGR of 21.2% from 2021 to 2028

InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company committed to developing cannabinoid-based pharmaceutical drug candidates. It also manufactures technologies for pharmaceutical-grade rare cannabinoids. It is known for creating a pipeline of cannabinoid-based pharmaceutical drug candidates to treat various diseases with high unmet medical needs. In a move to grow its market presence and strengthen its operations, the company announced that it had entered into a non-binding letter of intent (“LOI”) to acquire BayMedica Inc. (https://ibn.fm/WJSW5). This announcement followed the two parties’ reciprocal Research Collaboration Agreement back in November 2020, which saw them collaborate on several projects since (https://ibn.fm/WJSW5). The agreement allowed BayMedica to assess particular elements of InMed’s proprietary IntegraSyn(TM) approach in producing cannabinoids. In addition, InMed began a preclinical investigation of different compounds selected from BayMedica’s extensive library of proprietary cannabinoid analogs, designed to be developed to treat human diseases. While making the announcement, Eric A. Adams, the president and chief executive officer (“CEO”) of InMed, noted: “We are very excited about the prospect of continuing to work with BayMedica and the potential to build a leading rare cannabinoid company together (https://ibn.fm/WJSW5).” He further noted that: “Since commencing our collaboration in November last year, it has become apparent that our complementary business models and capabilities have the potential to provide a platform to expedite the growth of both companies and provide the flexibility of multiple processes for the manufacturing of rare cannabinoids.” The acquisition is intended to turn InMed into a powerful cannabinoid manufacturing company. With the company’s IntegraSyn(TM) pharmaceutical-grade manufacturing process, along with BayMedica’s rare cannabinoid manufacturing and ongoing revenue generation, Mr. Adams reckons that the company’s overall value proposition to customers would increase significantly, all while allowing the company to position itself at the forefront of the growing rare cannabinoid sector (https://ibn.fm/T8sD8). BayMedica is a biotechnology company that utilizes its expertise in synthetic biology and pharmaceutical chemistry to develop scalable, efficient and proprietary manufacturing approaches (https://ibn.fm/2068U). With this, it is known to produce regulatory-compliant, high-quality rare cannabinoids designed for the consumer market. Currently, BayMedica is commercializing the rare cannabinoid cannabichromene (“CBC”) as a business-to-business (“B2B”) supplier to distributors and manufacturers who are providing it in the health and wellness sector. The company is targeting additional rare cannabinoid launches for 2022. InMed is committed to becoming a leader in the cannabinoid sector. This move to acquire BayMedica confirms its ambition, along with the successful collaboration that the two companies have had so far. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• Brain Scientific poised to disrupt neurology market with two new FDA-cleared patented products that provide cost-effective brain imaging in any setting
• Current global market for EEG devices estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026

With a focus on developing innovative and proprietary medical devices and software, Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with two new FDA-cleared products that provide next-generation solutions to the neurology market. Already patented in the United States, China and Europe, the company’s first commercialized devices — the NeuroCap(TM) and NeuroEEG(TM) — are designed to disrupt the current electroencephalogram (“EEG”) market by offering a cost-effective and disposable alternative to existing solutions. The NeuroCap is a disposable pre-gelled EEG headset that features 22 electrodes and 19 active EEG channels that all adhere to the international 10-20 system. Cleared by the FDA in 2018, the headset can be used for recording EEGs in nearly any setting, including neurology clinics, remote clinical research labs, emergency departments, urgent care clinics, ICUs, nursing homes and assisted living facilities. Intended for prescription use, the NeuroEEG is a compact, portable and cost-effective FDA-cleared, clinical-grade wireless EEG amplifier that acquires, records, displays and transmits electrical brain activity for patients of all ages. Both the NeuroEEG and NeuroCap are delivered by MemoryMD Inc., the predecessor and now wholly owned subsidiary of Brain Scientific. Brain Scientific’s development process spans three stages. The first development phase, from 2018 to 2019, resulted in the inception of the company’s portable, clinical-grade, easy-to-use neurological devices. The second, ongoing phase currently focuses on the creation of cloud-based, secure infrastructure to transmit patient data between patients and neurologists. The final and third phase — scheduled for 2021-2023 — aims to focus on the use of AI to facilitate diagnostic analysis and increase the consistency, efficiency, consistency and accuracy of imaging by neurology specialists. Brain Scientific plans on expanding the vision for telemedicine in neurology with an aim to address the current acute neurologist shortfall throughout the U.S. The current global market for EEG devices is estimated at $956.1 million with an expected CAGR of 8.7% from 2019 to 2026 and is expected to reach $1.6 billion by 2026 (https://ibn.fm/Ys8Qi). With its current marketing strategy and development pipelines, BRSF’s management projects significant market penetration in addition to opportunities to collaborate with other businesses — such as EEG manufacturers — that could package Brain Scientific’s solutions with their products and effectively expand the company’s addressable target market. Headquartered in New York, Brain Scientific and its wholly owned subsidiary MemoryMD Inc. were founded in 2015 and went public in 2018. With a focus on developing innovative medical devices and software that disrupt the brain diagnostics market, Brain Scientific is poised to take center stage with solutions that enable medical professionals to cost-effectively diagnose patients with consistency, efficiency and accuracy in virtually any setting. For more information on Brain Scientific Inc., visit the company’s website at www.BrainScientific.com/Invest-Now. NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• The updated Fan Pass platform features a slew of upgrades including an updated web design and an enhanced user interface/user experience
• The monthly subscription for fans to access the Fan Pass platform is less than a digital download, only $2.99 per month for an All-Access VIP experience
• The company plans to add NFTs to its offering and has a signed Letter of Intent with Santo Blockchain Labs and Santo Mining Corp.
• Fan Pass will continue to monetize livestream events, merchandise and fan subscribers — increasing revenue opportunities for the artists who sign up for the platform

Mobile technology and entertainment company Friendable (OTC: FDBL) released an updated version of its Fan Pass artist livestreaming platform to the app stores on July 24, 2021, exactly on the one-year anniversary of the platform. The corporate milestone includes the delivery of version 2.0 of the platform, making it available on Google Play and the Apple Store. The new version offers an all-new UI/UX experience, updated feature sets for the artists and fans, and accelerates the onboarding process and dashboard features. Version 2.0 also includes an updated and refreshed web design. “Our talented development team worked hard to release v2.0 on the anniversary of our original launch. We believe there are more good things to come as artists currently using our platform discover how we’ve improved their ability to monetize livestream events, merchandise and fan subscribers,” Friendable CEO Robert A. Rositano Jr. said, commenting on the release (https://ibn.fm/CVE2I). “We expect the new features to also reach artists and fans who have not yet experienced our exciting app as we continue to rapidly meet the demands of our growing userbase.” The Fan Pass team is available to help guide artists through the complex process of making a name for themselves. They can do this without the complications and legal hurdles that are present when working with a record label. By leveraging the now available Pro Services, artists are able to build their brand, attract more fans and earn income as a musician with quality artist logo graphics and merchandise designs. Pro Services are easily navigated, with any artist interested being required to first fill out a form, which contains a short survey. Next, designers create a few designs based on the artist’s inspiration and send them the drafts for approval. Once approved, the graphics are delivered to the artist. Artists can get started by visiting https://proservices.fanpasslive.com. Pricing begins at $45 for basic social ad designs to promote the next three artist events. Fans can access their favorite artists on the platform by paying a monthly fee ($2.99), which costs less than a digital download. The All-Access VIP experience provides fans with access to:

• Live music and online concerts
• Backstage meetups — before, during and after live streams
• Livestreams and studio sessions
• Behind-the-scenes footage of music videos and photoshoots
• Special interviews and one-on-one videos
• Streams that highlight the day in the life of the artist

Fans have access to browse upcoming events, shop merch, search by genre, and interact with other fans and artists. Fans can view notifications and discussions while watching their favorite artists in one spot. Above all else, fans can feel good supporting the independent artists they love. As part of its strategy to continue to increase revenue-generating opportunities for its members, Fan Pass plans to add non-fungible tokens (“NFTs”) to its offering. NFTs are a unit of data that is stored on a digital ledger (blockchain) and certifies that a digital asset is unique and not interchangeable. NFTs are representative of items such as photos, videos, audio, and other types of digital-based files. Friendable has already signed a Letter of Intent (“LOI”) with Santo Blockchain Labs and Santo Mining Corp. (OTC: SANP) to develop global entertainment and music artist-driven NFTs, as well as a dedicated “Fanpasscrypto” marketplace. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• TAAT flagship product also earned distinction as second runner-up to Best in Show.
• “Awards are excellent indicator of how product is received by an audience of buyers keen to embrace concepts such as ours,” says CEO.
• Trade shows are key pieces in company’s strategic plan to grow presence, awareness in the tobacco industry.

In its first convention appearance since launching in October of last year, TAAT(TM) Global Alternatives’ (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP2) flagship product was named Best New Product and earned the second-highest honor as Best in Show. The company began a round of trade shows by participating at the HQ Event, a business-to-business (“B2B”) trade show for specialty lifestyle vendors, including purveyors of vaping and combustible smoking products, held in Las Vegas. “Alternatives to tobacco cigarettes such as vaping and herbal cigarettes have long been popular product categories at trade shows as demand persists from smokers aged 21+ for better choices,” stated TAAT CEO Setti Coscarella. “Now that in-person events such as B2B trade shows are back in operation, we are excited to be able to exhibit TAAT(TM) to buyers from around the globe who are attending shows such as the HQ Event and CHAMPS. I believe the two awards TAAT won at the HQ Event this week are an excellent indicator of how our product is received by an audience of buyers keen to embrace concepts such as ours.” The TAAT booth at the two-day HQ Event featured the complete line of TAAT product in Original, Smooth and Menthol; the exhibit saw a steady stream of interested conference attendees, all eager to learn more about TAAT’s game-changing tobacco-free, nicotine-free alternative to traditional cigarettes. Throughout the show, which was held July 21–22, 2021, company reps answered questions, provided information and built an invaluable network of wholesale and retail buyers from around the country. These trade shows are key pieces in the company’s strategic plan to grow its presence in the tobacco industry. TAAT executives plan to continue to exhibit at key conventions and trade shows as the company focuses on bringing TAAT to the $814 billion global tobacco industry. TAAT’s Beyond Tobacco(TM) cigarettes provide an alternative option unlike any other — a smooth, satisfying experience that mirrors traditional smoking. With TAAT, users can enjoy a tobacco-like scent and taste along with hand-to-mouth and flicking ashes motions — all without any actual tobacco and nicotine. To learn more about this company, visit www.TryTAAT.com and www.TAATGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at https://ibn.fm/TOBAF

• Team is always looking for ways to support dedicated brand partners in growing their businesses
• New materials include Spanish-language sizzle videos, product-marketing assets and other sales tools
• Company recently announced plans to unveil entire U.S. product line to customers in 21 European countries

Sharing Services Global (OTCQB: SHRG) and its subsidiary The Happy Co. have unveiled new Spanish-language resources to support the growing U.S. Latino market, as well as other Spanish-speaking countries around the globe (https://ibn.fm/jgET7). The Happy Co. is a leading producer and distributor of nootropic, functional beverage products with a focus on health and wellness. “Our team is always looking for new ways to better support our dedicated brand partners in growing their businesses,”said Bo Short, CEO of The Happy Co., formerly Elevacity International Holdings LLC. “While this is just a first step, it is one that puts us on a good path to empowering our field to build globally.We’re excited to share these resources and continue identifying new ways to support our community of entrepreneurs in achieving their business goals.” The new materials include Spanish-language sizzle videos, product-marketing assets and other sales tools to support Latino brand partners who are working to grow their businesses with The Happy Co. Recently, the company announced several growth initiatives, including its plan to unveil its entire U.S. product line on an NFR basis to customers in 21 European countries. The Happy Co. launched in February 2021 with an established foundation of distinctive nootropic products. The company offers functional beverages, capsules, patches and creams that elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat, tighten skin, and make you look, feel and perform like a younger person. The products are nootropics, or nutraceutical formulations derived from food sources that provide health benefits above and beyond basic nutritional value. Although the company does produce superior products, its mission is to provide its business partners and consumers with much more than that. “We are a lifestyle and a dose of happy,” the company’s slogan proclaims. A publicly traded company specializing in the direct-sales sector, Sharing Services Global Corporation is dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Drug delivery platform developer Lexaria Bioscience has developed its patented DehydraTECH(TM) as a means of transforming pharmaceuticals that increases their bioavailability and speed of efficacy
• Ongoing testing of DehydraTECH in combination with cannabidiol (“CBD”) is analyzing DehydraTECH’s responsiveness to hypertension conditions that are targeted in heart disease and stroke therapies
• Partial results from the company’s first study indicate Lexaria’s DehydraTECH platform, when processed with CBD, reduces blood pressure and does so much more rapidly when compared with the generic CBD controls
• The complete results of the study will be produced as sample and data analyses work are completed
• Lexaria is already under way on a second study that examines the efficacy of DehydraTECH-enabled CBD in repeat dosing, and the company anticipates positive outcomes based on the partial results of the first study that were just released

Ongoing clinical studies of the DehydraTECH platform’s ability to render therapeutic drugs into a powder or liquid form that increases their ability to be rapidly absorbed by the body without adverse changes to the original substances have yielded important new findings on the blood pressure and heart disease fronts. Bioavailability technology innovator Lexaria Bioscience (NASDAQ: LEXX)  announced partial results from its human clinical study HYPER-H21-1 on July 29, which is evaluating cannabidiol (“CBD”) processed with DehydraTECH, to determine its potential against hypertension. The initial results show DehydraTECH-enabled CBD produced a reduction in blood pressure in both male and female volunteers and was most pronounced in comparison against generic CBD controls during the first 10 to 50 minutes after administration, adding to Lexaria’s evidences that DehydraTECH-enabled drugs take effect more rapidly than generic controls, according to the company’s news release (https://ibn.fm/ps9d7). “We are very encouraged by these early results in our 2021 hypertension program. Lexaria’s technology enabled a rapid and sustained drop in blood pressure, especially systolic pressure and particularly in Stage 2 hypertensive volunteers,” Lexaria CEO Chris Bunka stated in the news release. According to the U.S. Centers for Disease Control and Prevention (“CDC”), heart disease is the leading cause of death for men, women and most classifications of people divided by racial and ethnic groups in the United States. One in every four deaths is attributed to heart disease alone, and the costs of related health care, medicines and lost job productivity exceed $200 billion each year (https://ibn.fm/obXUx). Multiple studies involving people with high, average and below-average levels of blood pressure have shown that lowering blood pressure reduces the risk of heart disease and stroke in all of those categories, which is a basis for prescribing blood-pressure-reducing drugs to the population at large based on risk factors of age and prior heart disease events regardless of periodic blood pressure checkup results (https://ibn.fm/C0y58). Blood pressure drugs and related medications have thereby resulted in a multi-billion-dollar industry. Lexaria’s partial results show its greatest comparative reduction from baseline was in systolic pressure, but there were also marked reductions in relative diastolic pressure from baseline and relative mean arterial pressure from baseline against the generic CBD controls. “Other studies of coronary heart disease (‘CHD’) have concluded that ‘lowering systolic pressure by 10 mm Hg or diastolic pressure by 5 mm Hg using any of the main classes of drugs reduced CHD events (fatal and nonfatal) by about a quarter and stroke by about a third, regardless of the presence or absence of vascular disease and of pretreatment BP. Heart failure is also reduced by about 25%,” Lexaria’s news release states. The company also noted that all of the study’s participants tolerated the DehydraTECH-enabled CBD without any serious adverse events or side effects, while some participants who used the concentration-matched, generic CBD control reported unwanted side effects such as gastrointestinal distress including diarrhea. Lexaria will provide an update on this study when sample and data analyses work for are complete. The company is optimistic that the partial results reported thus far are predictive of further enhanced efficacy through repeat dosing being analyzed in its second human clinical hypertension study, HYPER-H21-2, which is already under way (https://ibn.fm/j5sG0). A third planned human clinical hypertension study will be conducted this year once the results of HYPER-H21-1 and HYPER-H21-2 are carefully evaluated. The company also anticipates inflammatory marker assessments may ultimately be applicable to its research in the antiviral therapeutics space for potentially treating COVID-19 and other common pro-inflammatory conditions. Lexaria has already successfully demonstrated DehydraTECH usefulness in that area (https://ibn.fm/N6H6u). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Total number of paid tests and paid cancer tests increased significantly in Q2 over Q1
• The company’s approach to multi-cancer screening is called Cancer Differentiation Analysis (“CDA”) that is powered by a database of over 200,000 samples and cases, changing the way to approach disease and cancer screenings
• The global cancer diagnostics market size is expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening, detection, and cancer treatment, announced that it experienced strong growth in test volume in the first half of 2021. The total number of paid customers and testing volume increased almost 110% compared to the same period in 2020. Additionally, Q2 saw the total of paid tests and paid cancer tests increase by approximately 280% and 270%, respectively. The company has also seen growth in the new test products that it had launched in 2020 (https://ibn.fm/Josef). AnPac is a highly innovative company and an early thought leader, developing multi-cancer screening technology, which has gained significant acceptance. The company’s approach, Cancer Differentiation Analysis (“CDA”), uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments within the body before the tumors form. The CDA is powered by a database of over 200,000 samples and cases, serving as a new way to approach disease and cancer screenings. The device uses an integrated system of sensors to detect biophysical signals at the cellular, protein, and molecular level. CDA uses a proprietary algorithm to synthesize data, generating a personalized risk assessment for evaluating patients. “We are incredibly pleased with our strong test volume growth in the first half of 2021. We believe that our cost-effective, multi-cancer, high-performance cancer test packages are gaining increased customer and market acceptance,” AnPac CEO, Dr. Chris Yu, said while commenting on the testing volume increase. “We will work hard to continue commercialization in China and to achieve LDT approval in the U.S., allowing us to further accelerate our revenue growth.” With the significant market opportunities, increased customer and market acceptance, and given that historically the company has seen stronger test volume in the second half of the year compared to the year prior, AnPac expects the strong growth standard to continue through the remaining part of the year. The company has already made notable contributions to the cancer screening field. Compared to its industry peers, AnPac has 142 issued patents as of March 2021, whereas GRAIL, Inc. has 80 patents, and Thrive Earlier Detection Corp. only has 1 filed patent. As an early thought leader, the patent applications and IP for the company started in the early 2010s. By 2014, AnPac had already announced that the cancer detection product it developed was capable of screening 16 types of cancer, which was earlier than anyone else. These achievements help position AnPac as a leading entity on the global cancer diagnostics market, an expanding market expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period. This growth can be attributed to the innovation of new products and the rising urgency for early cancer detection. The rise in cancer incidents is demanding better screening and modalities used for monitoring disease progression (https://ibn.fm/3Vylk). Through its CDA technology, AnPac aims to tackle multiple aspects and challenges of the industry, including innovation, detection, identity, results, and biophysical properties. Through the test samples, CDA has been able to diagnose and identify pre- and early-stage cancers in patients that were previously diagnosed as cancer-free through traditional methods. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

• As U.S. research restrictions are lifted there is a rising interest in the use of plant-therapy in sports medicine
• Cannabis in sports medicine took center stage at the Tokyo Olympics
• American athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of an overall sports recovery plan

RYAH Group (CSE: RYAH) (formerly RYAH Medtech), the leader in dose-control technology for plant-based medicine, works with researchers to provide a full turnkey solution for clinical studies from start to finish. RYAH Group’s dose-control devices standardize the dosing protocol, QR products ensure compliance, and mobile apps collect the necessary data. As research restrictions throughout the U.S. lift, RYAH Group is standing by, ready to provide IoT hardware, software, and data analytics that reduce variations in patient-related clinical trials. One of the areas that the U.S. is poised to explore is cannabis in sports medicine. Cannabis in sports medicine is a controversial topic and is often not tolerated in professional and collegiate organizations. However, it’s also a topic that took center stage during this year’s Tokyo Olympics. The World Anti-Doping Agency (“WADA”) removing CBD as a prohibited substance in 2017 combined with the 2018 Farm Bill helped change the conversation around CBD use for athletes. As a result, American athletes are turning more and more to cannabis as a pain reliever, alternative to opioids, and part of a recovery plan. Megan Rapinoe is an advocate for the use of CBDs in sports recovery. She has incorporated it into her everyday recovery plan but was unable to continue while competing in Tokyo. Rapinoe shared that not being able to take the products she has been using to manage her pain, inflammation, mood, and sleep at the Olympics is “quite frustrating.” “We’re expected to perform on the biggest stages and highest levels, yet we can’t use all-natural products to help us recover,” stated Rapinoe (https://ibn.fm/ExEkd). “It’s not right, and these policies need to be changed to reflect where our culture is.” The NFL is leading the way forward in exploring the benefits of plant-therapy for players. The NFL and the NFL Players Association (“NFLPA”) announced on June 8, 2021, they are investing $1 million in funding for novel pain treatments that include cannabis and CBD therapy (https://ibn.fm/GiVM9). They will be providing five research grants to eligible applicants by November of 2021. From 2014 to 2020, the NFL had 801 injures and a 30 percent jump in reported concussions. The NFL is looking for alternatives to opioids, and it seeks out answers to the effectiveness, dosing requirements, and effect of the performance alterations of cannabis. Until now, there hasn’t been studies done regarding sports medicine directly. The NFLPA is changing this. Sports organizations across the U.S. must rethink their strict policies with the legalization of recreational and medicinal cannabis across the U.S. The good news is that with these new studies around plant therapy in sports medicine, a new era of pain management and recovery accepted by sports organizations worldwide may lie right around the corner for athletes like Rapinoe. RYAH Group is working alongside researchers globally, providing a holistic approach to therapeutic plant treatment and unlocking the data from seed to consumption. The company’s in-depth analytical reports help to identify significant trends, like the one in sports medicine, in plant therapy For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• The company has the ability to rent out properties on Airbnb at scale
• reAlpha has raised more than $6 million in two funding rounds led by $1.3 billion real estate group Crawford Hoying
• As of July 2021, reAlpha is testing the waters on a Reg A public offering to raise $75 million
• The company plans to spend $1.5 billion to acquire short-term rental properties
• reAlpha’s use of technology and relationships with lending institutions allow it to analyze thousands of properties per minute and purchase hundreds of properties at a time
• reAlpha forecasts annual revenue of $434 million by 2025
• The total asset value of the global short-term rental property market is estimated at $1.2 trillion

reAlpha is the Robinhood of Airbnb investments, representing the intersection of modern technology and lasting assets. A new wave of investment opportunities in real estate has emerged, and Airbnb short-term rentals are changing hospitality and travel on a global scale. Previously, only accredited investors have had access to the best real estate deals, but reAlpha is democratizing this lucrative new model, empowering anyone to generate wealth as a reAlpha member. reAlpha uses its proprietary, disruptive technologies to level the playing field, unraveling the industry’s high barriers to entry and bringing the power of real estate investing to the “99 percent.” The company’s unique model allows investors to benefit from both the superior returns of short-term rental income and increases in property value through renovation and appreciating markets. reAlpha likens this double investment return to seeing two desserts on a dinner menu and ordering both. The company seeks to open up access to real estate investing by letting regular people buy fractional ownership of short-term rentals using reAlpha’s smartphone app. The reAlpha app simplifies the real estate investing process. In the app, investors can check out the company’s most current properties offered for investment. If they choose to invest, they become members of a syndicate invested in a specific short-term rental property. Syndicate members receive quarterly dividend payments from rental revenue generated by the property in which they invested. The reAlpha model merges the most historically stable asset – real estate – with technology and the sharing-economy business model of the future – Airbnb. The company handles all property management functions and believes short-term rentals are no longer purely transactional and occupancy-driven. reAlpha reimagines the entire guest experience end-to-end to make sure the reAlphaHouse is the ultimate on-demand rental property. The company plans to implement various technologies, including smart locks, voice-activated electronics, home automation systems, and innovative furnishings, to create an unparalleled guest experience. When guests have exceptional stays, investors enjoy maximized profits. How it Works reAlpha has identified specific markets in which to purchase short-term rentals across the globe. The company prefers to buy 100 to 500 properties in each market. reAlpha uses artificial intelligence technology, dubbed reAlphaBRAIN, to select “unicorn properties,” the best available opportunities in the market for investment. The AI software can quickly evaluate thousands of property listings based on 25+ factors and assign each a reAlphaScore, projecting how Airbnb Viable the property is, as well as its projected value in the housing market. For a minimum investment of $2,500, an investor can purchase equity in a specific reAlpha property, similar to how they would buy stock or shares in a company. reAlpha matches the investor with other like-minded backers to form a syndicate, so together they can cover a down payment on the selected property. Investment properties usually require a down payment of 25 percent of the purchase price, but, with reAlpha properties, the down payment is only 10 percent because of the company’s relationships with lenders, making the initial investment more affordable. reAlpha maintains a majority stake in each investment syndicate, retaining 51 percent ownership in each purchased property and ensuring their interests are always aligned with investing members. Properties are typically refinanced after 12 to 16 months, freeing equity for reinvestment in additional properties. The company uses its AI software to predict optimum timing to sell properties in order to extract maximum value for investors. Gains are reinvested in additional properties. However, reAlpha also believes that real estate investing is more than financial returns. It includes the pride of ownership and the freedom of financial security. reAlpha members have access to their property when it is not rented out on Airbnb. The company is driven every day to create not only lucrative returns for its members but also to deliver exceptional experiences and positive impact in the communities in which reAlpha lives and operates. Market Outlook There are an estimated 7.4 million short-term rental properties worldwide. The total asset value of this global market is projected at $1.2 trillion. In the U.S. there are about 1.8 million short-term rental properties. These have an estimated asset value of $933 billion. Brain Chesky, the CEO of Airbnb, recently stated that there is a shortage of properties to meet demand and that the company will need “millions of more hosts.” reAlpha is projecting that the company and its investors will own 5,000 short-term rental investment properties by 2025. reAlpha forecasts annual revenue of $434 million by 2025. Management Team Giri Devanur is the CEO and co-founder of reAlpha. Prior to founding reAlpha, he served as president and CEO of enterprise software company Ameri100 Inc. from its founding in 2013. He scaled Ameri100 from zero to $50 million in revenue and took the company public in 2017. That same year, he was named E&Y Entrepreneur of the Year. He immigrated to the U.S. with virtually no possessions and $65 in the bank. He earned a Master’s in Technology Management from Columbia University, where he continues to mentor aspiring entrepreneurs. Monaz Karkaria is the COO and co-founder of reAlpha. Prior to reAlpha, she founded real estate management firm Ben Zen Properties LLC. She has also worked in branch operations for Citibank. Before her involvement in Citibank, she worked at Berlitz in Sao Paulo, Brazil, as an ESL business coach and consultant for various international business clients like GE, Google, PepsiCo and others. She began her career in sales and marketing at Smith & Nephew Dubai. She is also a popular real estate coach and speaker. Mike Logozzo is the CFO of reAlpha. Prior to joining the company, he served as Managing Director, Americas for innovation advisory firm L Marks. Before that, he was General Manager, Financial Services Operations, Americas Region for BMW Group Financial Services, where he also held Special Projects Manager and CIC Strategy Manager positions. Christie Currie is the CMO of reAlpha. Previously, Christie launched her own business in the MedTech space, Zandaland, where she worked closely with large enterprises and health care systems. Currie’s work in the startup community led her to London-based corporate innovation firm L Marks, where she led world-leading corporations in retail, supply chain and logistics, and health care to identify strategic areas of need and successfully engage industry-disrupting startups. Currie has mentored hundreds of these startups, helping them to align their technology solutions with market needs. For more information, visit the company’s website at www.reAlpha.com. NOTE TO INVESTORS: The latest news and updates relating to reAlpha are available in the company’s newsroom at https://ibn.fm/reAlpha

• FingerMotion recently announced it has submitted an application to be uplisted to NASDAQ
• The company believes listing its shares of common stock on the Nasdaq Capital Market, which is subject to approval and fulfillment of applicable requirements, will improve liquidity, increase its corporate visibility, and enhance shareholder value
• FingerMotion’s first upgrade came in February 2019, when it announced it had been uplisted and approved to trade on the OTCQB Venture Marketplace
• In January 2021, the company was again uplisted to the OTCQX, where it currently trades and will continue trading until its application to join the NASDAQ is approved

FingerMotion (OTCQX: FNGR), an evolving technology company with core competence in SMS/MMS as well as mobile payment and recharge platform solutions in China, recently announced it has applied to have its shares of common stock listed on Nasdaq Capital Market, subject to NASDAQ’s approval and fulfillment of all applicable listing, governance, and regulatory requirements (https://ibn.fm/7quFq). “Over the past year, we have been working diligently to comply with certain uplisting requirements,” said FingerMotion CEO Martin Shen. “Applying for a NASDAQ listing is a key milestone in our company’s evolution. We believe listing our common stock on the Nasdaq Capital Market will improve liquidity, increase our corporate visibility, and enhance shareholder value.” If approved, Shen noted, the uplisting will see FingerMotion join the ranks of global technology companies listed in the US. It will also mark stellar progress whose beginning, outside of the company’s establishment in 2016 and growth through the years, can be traced to February 2019 when FNGR announced it had been upgraded from pink sheets to the OTCQB Venture Marketplace. At the time, Shen intimated that the uplisting to OTCQB served as a stepping stone to meeting the listing requirements for admission on a senior exchange (https://ibn.fm/MEhSq). In January this year when FingerMotion was again upgraded to the OTCQX Best Market (https://ibn.fm/1Bye6). The upgrade marked a significant milestone for the company as it offered, and continues to do so, greater access to the capital markets. It was also an essential part of FNGR’s business plan. “The higher standards make us more transparent to institutional investors who rely on the more rigorous review of the company,” said Shen, following the uplisting to OTCQX. “The liquidity on OTCQX should also provide investors more confidence to trade our securities. The higher financial standards and reporting requirements are good for management, strategic partners, and investors as it will increase our overall appeal to attract top-level experience, partnerships, and investment.” Until its uplisting application to NASDAQ is approved, FingerMotion will continue to trade on the OTCQX under its current ticker symbol “FNGR.” The company looks forward to updating shareholders on the progress of its submission in due course. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR